Crux Wealth Advisors Makes New $308,000 Investment in Sanofi (NASDAQ:SNY)

Crux Wealth Advisors acquired a new stake in Sanofi (NASDAQ:SNY - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 6,396 shares of the company's stock, valued at approximately $308,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Raymond James Financial Inc. acquired a new stake in shares of Sanofi in the 4th quarter valued at approximately $135,933,000. Boston Partners grew its stake in Sanofi by 86.4% in the 4th quarter. Boston Partners now owns 5,396,531 shares of the company's stock valued at $260,607,000 after acquiring an additional 2,501,073 shares during the last quarter. Magnetar Financial LLC raised its position in Sanofi by 104.3% during the fourth quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company's stock worth $161,103,000 after acquiring an additional 1,705,148 shares during the last quarter. DAVENPORT & Co LLC lifted its holdings in shares of Sanofi by 40.7% in the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company's stock valued at $110,715,000 after purchasing an additional 664,455 shares in the last quarter. Finally, Thrivent Financial for Lutherans increased its stake in shares of Sanofi by 36.0% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,943,761 shares of the company's stock worth $93,774,000 after purchasing an additional 514,542 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Down 0.1 %

Sanofi stock traded down $0.04 during trading on Wednesday, reaching $50.56. 6,232,522 shares of the company's stock were exchanged, compared to its average volume of 2,365,720. The company's 50-day moving average is $54.89 and its two-hundred day moving average is $52.30. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. Sanofi has a 52-week low of $45.22 and a 52-week high of $60.12. The firm has a market cap of $127.73 billion, a price-to-earnings ratio of 20.31, a PEG ratio of 1.01 and a beta of 0.57.

Remove Ads

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on SNY. BNP Paribas began coverage on Sanofi in a research note on Tuesday. They set an "outperform" rating and a $65.00 price objective on the stock. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. Finally, The Goldman Sachs Group started coverage on shares of Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Sanofi has an average rating of "Moderate Buy" and an average target price of $63.33.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.